AU Patent

AU2021275381A1 — Elafibranor for the treatment of primary sclerosing cholangitis

Assigned to Genfit SA · Expires 2022-11-24 · 3y expired

What this patent protects

The present invention relates to elafibranor or its active metabolite for use in a method for treating primary sclerosing cholangitis.

USPTO Abstract

The present invention relates to elafibranor or its active metabolite for use in a method for treating primary sclerosing cholangitis.

Drugs covered by this patent

Iqirvo (ELAFIBRANOR) · Ipsen

Patent Metadata

Patent number: AU2021275381A1
Jurisdiction: AU
Classification: —
Expires: 2022-11-24
Drug substance claim: No
Drug product claim: No
Assignee: Genfit SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.